Analyst Ratings February 12, 2026

Raymond James Lifts Cognex Target to $80 After Strong Q4; Opinions Among Wall Street Diverge

Firm raises price objective and EPS outlook after broad-based quarterly beat, while other banks offer mixed ratings amid valuation and cyclical concerns

By Leila Farooq CGNX
Raymond James Lifts Cognex Target to $80 After Strong Q4; Opinions Among Wall Street Diverge
CGNX

Raymond James increased its price target for Cognex to $80 from $50 and kept a Strong Buy rating following a fourth-quarter outperformance that exceeded the firm's revenue and EPS expectations. The company reported broad-based strength, especially in logistics, and outlined steps to improve operating leverage. Other major firms have issued contrasting views, with Goldman Sachs upgrading the stock and JPMorgan downgrading it.

Key Points

  • Raymond James raised its price target on Cognex to $80 from $50 and retained a Strong Buy rating after a fourth-quarter beat on revenue and EPS.
  • Cognex posted $971.71 million in trailing twelve-month revenue, a 10.23% increase, with logistics as a standout market.
  • Wall Street opinions diverge: Goldman Sachs upgraded to Buy with a $50 target, while JPMorgan downgraded to Underweight with a $35 target.

Overview

Raymond James raised its price target on Cognex (NASDAQ:CGNX) to $80.00 from $50.00 and maintained a Strong Buy rating after the machine vision supplier reported a better-than-expected fourth quarter. The firm highlighted an across-the-board beat, with revenues and earnings both coming in ahead of its internal forecasts.

Quarterly performance and valuation

According to Raymond James’ assessment, Cognex topped the firm’s top-line expectations by 8% and outperformed on adjusted earnings per share by 30% in the fourth quarter. The company has shown recent market momentum, delivering an 8.96% return over the last week and trading at $59.06, comfortably above its 52-week low of $22.67. InvestingPro data cited within the reporting indicates a price-to-earnings ratio of 90.33, suggesting a high valuation multiple.

Revenue and segment trends

Cognex reported revenue of $971.71 million for the trailing twelve months, reflecting 10.23% growth year over year. Raymond James noted that strength was broad across end markets, with particularly robust performance in the Logistics segment that supported the quarterly upside.

Operational changes and balance sheet

The company disclosed divestitures amounting to $22 million related to underperforming work and outlined a program intended to drive considerable operating leverage. Cognex provided guidance for margins through a cycle in the range of 25% to 31% and described organizational transformation efforts that include changes to corporate structure and go-to-market strategy.

Financial metrics cited in the reporting show a conservative leverage profile: a debt-to-equity ratio of 0.05 and total debt to capital of 0.01, indicating minimal debt on the balance sheet and what the article characterized as financial flexibility to support transformation initiatives.

Analyst outlook and model changes

Raymond James projects Cognex will exceed Street margin expectations by more than 500 basis points over the next few years. The firm raised its adjusted EPS estimates for 2026 and 2027 by $0.17 and $0.34, to $1.24 and $1.54, respectively, assumptions that the note attributes to projected low-double-digit organic growth. With organizational optimization underway and macro tailwinds cited, Raymond James suggested a positive revision path in 2026/27 that could generate 15% to 20% top-line growth.

Contrasting views from other banks

Market participants have expressed differing perspectives on Cognex’s prospects. Goldman Sachs upgraded the stock from Sell to Buy and set a price target of $50.00, forecasting organic growth of 6% in 2025 and 7% in 2026 tied to logistics automation and recoveries in consumer electronics and packaging end markets. By contrast, JPMorgan lowered its rating from Neutral to Underweight and set a $35.00 target, citing valuation concerns and cyclical risks while acknowledging the company’s long-term potential in AI-enabled vision systems. These divergent assessments underscore mixed expectations among sell-side analysts.


Key takeaways

  • Raymond James raised its price target to $80 and kept a Strong Buy after Cognex beat Q4 revenue and EPS expectations.
  • Cognex reported $971.71 million in trailing twelve-month revenue, up 10.23%, with logistics cited as a notable strength.
  • Other major firms are split: Goldman Sachs upgraded to Buy with a $50 target while JPMorgan downgraded to Underweight with a $35 target.

Risks and uncertainties

  • Valuation risk - The company’s P/E of 90.33 signals a high multiple that factored into JPMorgan’s downgrade and presents a potential headwind for investors if growth expectations soften.
  • Cyclical exposure - JPMorgan flagged cyclical risks, which could affect Cognex if demand in end markets such as consumer electronics and packaging does not recover as anticipated.
  • Execution risk related to transformation - Cognex has announced divestitures and organizational changes intended to improve margins; the success of those initiatives will be material to achieving the 25%-31% through-cycle margin target.

Sectors impacted

  • Industrial automation and logistics - performance in logistics was highlighted as a primary source of strength.
  • Consumer electronics and packaging - cited as areas where recoveries could contribute to future growth.

Risks

  • Valuation risk due to a P/E of 90.33, which may pressure the stock if growth expectations are not met.
  • Cyclical exposure in end markets such as consumer electronics and packaging could dampen demand and revenue.
  • Execution risk tied to divestitures, organizational restructuring and the company’s ability to reach a 25%-31% through-cycle margin.

More from Analyst Ratings

HSBC Lowers Synopsys Rating to Hold, Flags 2026 as Transition Year Feb 21, 2026 DA Davidson Cuts Uber Price Target Citing Elevated Investment; Buy Rating Intact Feb 20, 2026 Freedom Capital Markets Raises Freeport-McMoRan to Buy, Cites Copper Supply Tightness Feb 20, 2026 BofA Lifts CF Industries Price Target After Strong Q4 EBITDA; Maintains Underperform Rating Feb 20, 2026 Truist Lifts Tandem Diabetes Price Target as Company Shifts Toward Pharmacy Model Feb 20, 2026